Compounder Draws Warning Letter for Misbranded, Unapproved Drugs
The FDA Philadelphia district office has issued a warning letter to a compounding pharmacy in Allentown, PA over misbranded drugs and sterility issues.
Source: Drug GMP Report
The FDA Philadelphia district office has issued a warning letter to a compounding pharmacy in Allentown, PA over misbranded drugs and sterility issues.
Source: Drug GMP Report